Chemo-proof T cells
Incysus's chemo-resistant γδ T cells could treat solid tumors
T cell therapies have shown unprecedented efficacy in hematologic malignancies, but haven’t produced the same results in solid tumors and have dangerous toxicities. By combining engineered, drug-resistant γδ T cells with chemotherapy, Incysus Ltd. has hit upon a strategy that may be safer and more effective against solid tumors than conventional T cell therapies.
The αβ T cells most T cell therapies use are antigen-specific and may not eliminate the entire tumor. Incysus relies on γδ T cells because they do not require antigen processing to detect target cells, and they penetrate and kill solid tumors more effectively than αβ cells. ...
BCIQ Company Profiles
BCIQ Target Profiles
Killer cell lectin-like receptor subfamily K member 1 (NKG2D) (KLRK1) (CD314)